The present disclosure relates to an LNA oligonucleotide consisting of a sequence selected from the group consisting of 5'-(<u style='single'>Tx)GxGxcsasasgscsastscscs<u style='single'>TxGxT-3' and 5'-(<u style='single'>Gx)TxTxascstsgscscststscsTxTx<u style='single'>A-3', wherein capital letters designate a beta-D-oxy-LNA nucleotide analogue, small letters designate a 2-deoxynucleotide, underline designates either a beta-D-oxy-LNA nucleotide analogue or a 2-deoxynucleotide, subscript 's' designates a phosphorothioate link between neighbouring nucleotides/LNA nucleotide analogues, and subscript 'x' designates either a phosphorothioate link or a phosphorodiester link between neighbouring nucleotides/LNA nucleotide analogues, and wherein the sequence is optionally extended by up to five 2-deoxynucleotide units. The LNA oligonucleotides are useful for modulating the expression of hypoxia-inducible factor-1a (HIF-1a), e.g. in the treatment of cancer diseases, inhibiting angiogenesis, inducing apoptosis, preventing cellular proliferation, or treating an angiogenic disease, e.g. diabetic retinopathy, macular degeneration (ARMD), psoriasis, rheumatoid arthritis and other inflammatory diseases.
Potent LNA oligonucleotides for the inhibition of HIF-1A expression